Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy
- PMID: 28242618
- DOI: 10.1136/annrheumdis-2016-210820
Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy
Keywords: Autoantibodies; Autoimmune Diseases; Autoimmunity; Sjøgren's Syndrome; Treatment.
Conflict of interest statement
Competing interests: Honoraria: SC for Bristol-Myers Squibb, Janssen, Merck Sharp & Dohme and Roche. LA for Novartis, Pfizer, BMS, Sanofi and Ipsen. OL for Merck Sharp Dohme and Genzyme.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
